Skip to content

The meta-inner humor therapy: Insights from a three-arm randomized controlled trial for comorbid emotional disorders.

Mehdi Akbari, Sonay Sheikhi, Roya Forootan, Gordon J. G. Asmundson

Journal of Anxiety Disorders March 17, 2026 DOI: 10.1016/j.janxdis.2026.103155 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Feasibility pilot and three-arm randomized controlled trial Peer reviewed
Sample size 120
Population Adults with comorbid emotional disorders; in the RCT, adults with at least one primary DSM-5 anxiety, depressive, or obsessive-compulsive disorder (mean 2.4 comorbid diagnoses)
Interventions Meta-Inner Humor Therapy (MIHT) Health-Enhancement Program (HEP) waitlist
Duration Ten weekly 90-minute group sessions; outcomes at baseline, post-treatment, and 9-month follow-up
Topics Depression Meditation
Keywords Humans Treatment outcome Feasibility studies Pilot projects Anxiety disorders Obsessive-compulsive disorder Comorbidity Adult Middle aged Female Metacognition Rct Psychological flexibility Repetitive negative thinking Active mindfulness Meta-inner humor
Key findings MIHT showed high feasibility (92.5% retention, 91% therapist fidelity) in the pilot and, in the RCT, produced significantly greater improvements than both the Health-Enhancement Program and waitlist across all primary and secondary outcomes. Changes in adaptive and maladaptive meta-inner humor beliefs uniquely predicted symptom reductions, partly via reductions in repetitive negative thinking and psychological inflexibility.

Abstract

Background: Meta-Inner Humor Therapy (MIHT) was developed to cultivate active mindfulness by integrating humor-based metacognition with mindful awareness. We evaluated this treatment protocol in a feasibility pilot (Study 1) and a three-arm randomized controlled trial (RCT; Study 2).

Method: In Study 1, 27 adults with comorbid emotional disorders completed ten weekly 90-minute group sessions of MIHT. In Study 2, 93 adults (59% female; mean age=32.6; SD= 9.9), each with at least one primary DSM-5 anxiety, depressive, or obsessive-compulsive disorder (mean comorbidity diagnosis = 2.4), were randomized to MIHT, a Health-Enhancement Program (HEP), or waitlist. Outcomes were measured at baseline, post-treatment, and 9-month follow-up.

Results: Study 1 showed high feasibility (92.5% retention) and strong therapist fidelity (91%), with preliminary within-group symptom reductions. In Study 2, MIHT produced significantly greater improvements than HEP and waitlist across all primary and secondary outcomes. Primary outcomes were emotional symptoms, including anxiety, depression, stress, and obsessive-compulsive symptoms. Secondary outcomes included repetitive negative thinking, mindfulness, and adaptive/maladaptive meta-inner humor beliefs. Changes in adaptive and maladaptive meta-inner humor beliefs (MIHBs) uniquely predicted reductions in emotional symptoms after accounting for mindfulness-related improvements. Mediation analyses indicated that MIHB change was associated with reductions in repetitive negative thinking and psychological inflexibility which, in turn, contributed to reductions in anxious, depressive, and obsessive-compulsive symptoms. Treatment effects remained significant following multiplicity correction and were robust across all clustering sensitivity checks, confirming the stability and reliability of MIHT advantages.

Conclusions: Across a pilot and an RCT, MIHT demonstrated strong feasibility, acceptability, and clinical efficacy. By transforming passive observation into engaged, compassionate inner playfulness, MIHT may represent a scalable transdiagnostic intervention for targeting cognitive-emotional rigidity.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics